Company: APM
Filing Date: 2025-10-06
Form Type: S-4
Source: 0001213900-25-096656
Chunk: 335

Company: Aptorum Group Ltd
Filing Date: 2025-10-06
Form: S-4
Chunk 335
---
 period of time through which its financial resources will be adequate to support its operations is a forward -lookingstatement and involves risks and uncertainties, and actual results could vary as a result of a number of factors, including the factors discussed in the section entitled “Risk Factors” and elsewhere in this proxy statement/prospectus. DiamiR has based this estimate on assumptions that may prove to be wrong, and it could utilize its available capital resources sooner than currently expected.

186 DiamiR’s future funding requirements, both near- and long -term, will depend on many factors, including, but not limited to: •the initiation, progress, timing, costs, and results of clinical validation for CogniMIR ® •the terms and timing of any future collaboration, licensing, or other arrangements that DiamiR may establish; •the outcome, timing, and cost of meeting regulatory requirements; •the cost of obtaining, maintaining, defending, and enforcing intellectual property rights, including patent rights; •the effect of competing technological and market developments; •market acceptance of CogniMIR ®if DiamiR meets regulatory requirements for its commercialization; and •the extent to which DiamiR acquires, licenses, or invests in businesses, products or technologies. Until DiamiR can generate a sufficient amount of revenue from CogniMIR ®and related services and products, if ever, DiamiR expects to finance future cash needs through public or private equity offerings, debt financings or grants. Additional funds may not be available when needed on terms that are acceptable to DiamiR, or at all. If adequate funds are not available, DiamiR may be required to delay, reduce the scope of or eliminate its commercialization efforts. To the extent that DiamiR raises additional funds by issuing shares of common stock, its shareholders may experience additional dilution, and debt financing, if available, may involve restrictive covenants. To the extent that DiamiR raises additional funds through collaborations and licensing arrangements, it may be necessary to relinquish some rights to its technologies or its product candidates or grant licenses on terms that may not be favorable to DiamiR. DiamiR may seek to access the public or private capital markets whenever conditions are favorable, even if DiamiR does not have an immediate need for additional capital at that time. DiamiR does not expect CogniMIR ®to be commercially available with reimbursement in place before fiscal 2027, if at all. DiamiR will need to raise